IP Library › Granted Patent US 11,744,845
Granted Patent B2
US 11,744,845 · App. 17/339,484 · Granted Sep 5, 2023

Compounds,compositions, and methods for the treatment of disease

Inventors: Radhakrishnan P. Iyer (Shrewsbury, MA); Anjaneyulu Sheri (Shrewsbury, MA); Seetharamaiyer Padmanabhan (Lexington, MA); Geeta Meher (Hopkinton, MA); Shenghua Zhou (Shrewsbury, MA); Sreerupa Challa (Shrewsbury, MA); Rayomand H. Gimi (Chelmsford, MA); Dillon Cleary (Norton, MA)
Assignee: F-star Therapeutics, Inc.
A61K31/7084A61K9/0019A61K9/0029A61K39/12A61K39/39A61K45/06A61P35/00C07H21/00A61K2039/55511
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,744,845
App. No.
17/339,484
Granted
Sep 5, 2023
Kind
B2
Abstract

Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

Claims (32)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is

6. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is

8. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the cancer is acute monocytic leukemia, lymphoma, melanoma, colon cancer, or breast cancer.

9. The method of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The method of claim 8 , wherein the compound is

11. The method of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 8 , wherein the compound is

13. The method of claim 8 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 8 , wherein the compound is

15. The method of claim 8 , wherein the cancer is colon cancer.

16. The method of claim 8 , wherein the cancer is breast cancer.

17. The method of claim 16 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The method of claim 16 , wherein the compound is

19. The method of claim 16 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20. The method of claim 16 , wherein the compound is

21. The method of claim 16 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

22. The method of claim 16 , wherein the compound is

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2024
From: F-STAR THERAPEUTICS, INC.
To: INVOX PHARMA LIMITED
Reel/Frame 068859/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2022
From: SPEROVIE BIOSCIENCES, INC.
To: F-STAR THERAPEUTICS, INC.
Reel/Frame 059415/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2021
From: IYER, RADHAKRISHNAN P.; SHERI, ANJANEYULU; PADMANABHAN, SEETHARAMAIYER; MEHER, GEETA; ZHOU, SHENGHUA; CHALLA, SREERUPA; GIMI, RAYOMAND H.; CLEARY, DILLON
To: SPEROVIE BIOSCIENCES, INC.
Reel/Frame 057163/0031 →
Continuity (10)
Continuation 16315472
Provisional Application 62508846 · May 19, 2017
Provisional Application 62470746 · Mar 13, 2017
Provisional Application 62462679 · Feb 23, 2017
Provisional Application 62444141 · Jan 9, 2017
Provisional Application 62411424 · Oct 21, 2016
Provisional Application 62403530 · Oct 3, 2016
Provisional Application 62363118 · Jul 15, 2016
Provisional Application 62359039 · Jul 6, 2016
Related Publication 20220054523A1 · Feb 24, 2022